Reolysin is a relatively new drug developed from a fairly harmless type of virus called a reovirus. Most of us will have been infected with one type of reovirus or another at some point.

In most normal healthy cells, reoviruses don’t usually cause problems, but scientists have found that they reproduce in some types of cancer cell, killing them in the process. Not only that, but it seems this process also helps the body’s immune system to recognise cancer cells and attack them.

Like all new discoveries, reolysin will have to be rigorously tested to prove that it‘s safe and has a lasting effect. Many potential new treatments that look really promising in the laboratory either don’t work in people, or turn out to be no better than the treatments we already have.

Early days

The media headlines were driven by the results of an early phase trial with reolysin, which was published in the journal Clinical Cancer Research. In this trial, the drug was given with other treatments like radiotherapy and chemotherapy.

The trial was small, and was trying to establish if the drug was safe and if it had any effect on tumours in humans. Only 23 patients took part, but 14 of them seemed to show a response to the treatment – their tumours either stopped growing or shrank.

But so far, the progress of these patients has not been followed for very long. Larger trials are needed to find out if the effects seen in this trial were genuinely down to reolysin, or due to the other treatments the patients were receiving. Researchers also need to find out whether the effects of reolysin on cancers are long lasting, and to compare it with other treatments to see which is best.

As is often the case with research, it’s likely to be a few years before we know the answers to these questions. If these trials are successful, it will be longer still before the treatment becomes widely available, as the drug will need to be evaluated by medical regulators like the National Institute for Health and Clinical Excellence. We don’t know of any trials currently going on that people can join.

The journalists did a good job in reporting accurately on this drug. All the articles we read made it clear that the treatment wasn’t available yet and that the long term effects were unknown – although, as is often the case, the headline writers at some newspapers may have got a bit over-excited.

Wider impact

But reading about potential breakthroughs can have quite an impact on some people with cancer, especially those whose cancer cannot be cured. We had a lot of calls to our helpline from people who wanted to know if they could get hold of the drug, or join a trial.

Our nurses are skilled at responding to these types of enquiries. Even if people are very distressed or desperate for some hope, they are able to help them come to terms with the fact that a new drug or treatment they’ve read or heard about isn’t available yet, and that we don’t yet know how well it works.

The nurses who write for our website CancerHelp UK also had the page on reolysin updated the day the story broke, giving people with questions about it somewhere to go for reliable information. The website also has a database of clinical trials that people can look through to see if there are any trials that they might be able to join (although there aren’t any reolysin trials recruiting at the moment).

It is really important that the public get to hear about new developments in cancer treatment. It helps to give hope and shows that scientists and clinicians are really making progress. But it’s also important that organisations like us provide services like our helpline and patient information website. With empathy and compassion, we can help people understand what the significance of a new discovery is.

More on this topic

Tags

Comments

I knew that. But the value of multiple locations is that approval – if successful – can come in multiple countries which makes a big difference commercially. So for purposes of market share, it’s three studies.

toeser – there’s only one Phase 3 trial, for head and neck, however it’s taking place in 3 different countries, which is perhaps where the confusion arises. The results from the 25 different centres taking part in this trial will be merged for analysis.

Oncolytics Biotech is planning more Phase 3s, and non small cell lung cancer (NSCLC) is a likely candidate depending on the results coming out of the current Phase 2 trial.

Maybe relatively new compared to Penicillin, but the Reovirus has been under heavy study for more than a decade. Numerous Phase I and Phase II trials have been successfully completed, and Oncolytics has just started two Phase III trials, with another just approved.

While in general accurate, I’m not sure this entry is correct regarding trials in the UK. On the Oncolytics Biotech website here: http://www.oncolyticsbiotech.com/clinical.html they list two ‘Ongoing’ trials in the UK (REO 013 for metastatic colorectal cancer, and REO 012 for a variety of advanced cancers).

Quick links

Follow us

Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666) and the Isle of Man (1103). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: Angel Building, 407 St John Street, London EC1V 4AD.